Cannabinoids and Sleep duration

In a systematic review and meta-analysis of polysomnographic cannabis studies involving 18 studies identified; 9 included in meta-analysis, researchers did not detect a difference in consistent objective sleep-architecture improvement in a cannabis review following varied across included studies over varied across included studies. The recorded comparator was varied across included studies. ¹

Recorded result: The review found no consistent alteration across objective sleep-architecture measures.

In a randomized placebo-controlled crossover pilot trial involving 20 adults with DSM-5 insomnia disorder, researchers reported a decrease in total sleep time after an acute THC-CBD dose following 10 mg THC and 200 mg CBD once by the oral route over single study night. The recorded comparator was placebo. ²

Recorded result: Total sleep time decreased by 24.5 minutes (P=.05; d=-.5).

In a randomized placebo-controlled crossover pilot trial involving 20 adults with DSM-5 insomnia disorder, researchers did not detect a difference in subjective sleep quality after an acute thc-cbd dose following 10 mg THC and 200 mg CBD once by the oral route over single study night. The recorded comparator was placebo. ²

Recorded result: No change in subjective sleep quality was detected.

In a randomized double-blind placebo-controlled crossover clinical trial involving 125 people with insomnia, researchers reported an increase in combined slow-wave and REM sleep percentage following 300 mg CBD plus 1 mg each of eight terpenes per administration by the oral route over 4 weeks. The recorded comparator was placebo. ³

Recorded result: Mean difference 1.3 percentage points (SE 0.60; 95% CI 0.1 to 2.5; P=0.03).

In a randomized double-blind placebo-controlled crossover clinical trial involving 125 people with insomnia, researchers did not detect a difference in total sleep time following 300 mg CBD plus 1 mg each of eight terpenes per administration by the oral route over 4 weeks. The recorded comparator was placebo. ³

Recorded result: The abstract reports no detected effect on total sleep time.

In a randomized double-blind placebo-controlled crossover clinical trial involving 125 people with insomnia, researchers did not detect a difference in resting heart rate following 300 mg CBD plus 1 mg each of eight terpenes per administration by the oral route over 4 weeks. The recorded comparator was placebo. ³

Recorded result: The abstract reports no detected effect on resting heart rate.

In a randomized double-blind placebo-controlled crossover clinical trial involving 125 people with insomnia, researchers did not detect a difference in heart rate variability following 300 mg CBD plus 1 mg each of eight terpenes per administration by the oral route over 4 weeks. The recorded comparator was placebo. ³

Recorded result: The abstract reports no detected effect on heart rate variability.

In a systematic review and meta-analysis of medical cannabis for adult insomnia involving adults with insomnia across included studies, researchers reported an increase in sleep improvement attributed to 50-to-300-mg CBD doses in an insomnia review following CBD 50 to 300 mg in the favorable review conclusion by the oral or sublingual across included studies route over varied across included studies. The recorded comparator was varied across included studies. ⁴

Recorded result: The abstract concluded that CBD doses of 50 to 300 mg were safe and effective for improving sleep; it did not report a CBD-specific pooled effect estimate.

In a double-blind randomized placebo-controlled crossover trial involving 20 healthy adult novice cannabis users, researchers did not detect a difference in later nighttime sleep after daytime low-dose thc-cbd oil following 1 mL once; cannabinoid milligrams not stated in the abstract by the oral route over single daytime dose with 7-day washout monitoring. The recorded comparator was placebo oil. ⁵

Recorded result: No treatment or time differences were detected for indirect nighttime sleep measures (all P>0.05).

In a small placebo- and active-comparator clinical trial summarized in a review article involving 15 volunteers with insomnia, researchers reported an increase in self-reported sleep duration in a historical insomnia trial following 40 mg, 80 mg, or 160 mg; positive sleep-duration report at 160 mg by the not stated in the PubMed abstract route over acute administration; exact schedule not stated in the PubMed abstract. The recorded comparator was placebo and 5 mg nitrazepam. ⁶

Recorded result: The 160 mg group reported significantly more sleep than placebo; the abstract gives no effect estimate or P value.

In a rat polysomnography study, researchers reported more total sleep time. This does not establish the same result in people. ⁷

In a rat polysomnography study, researchers reported more NREM sleep. This does not establish the same result in people. ⁷

In a rat polysomnography study, researchers reported more REM sleep. This does not establish the same result in people. ⁷